Clinical Trials Logo

Benzodiazepine Dependence clinical trials

View clinical trials related to Benzodiazepine Dependence.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06359314 Not yet recruiting - Anxiety Disorders Clinical Trials

Anxiety Lowering and Deprescribing Through Emotion Regulation

ALDER
Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test ALDER (Anxiety Lowering and Deprescribing through Emotion Regulation), an online self-guided positive emotion intervention, in patients over the age of 65 who are candidates for benzodiazepine receptor agonist (BZRA, commonly called benzos, or z-drugs) deprescribing. The main questions it aims to answer are: - Is ALDER relevant to and satisfactory for older adult BZRA users? - Does ALDER help to increase positive emotions and decrease anxiety, trouble sleeping, and use of BZRA medications? Participants will complete the 5-week online self-guided ALDER intervention as well as two survey assessments, one before the intervention and one after.

NCT ID: NCT05935553 Not yet recruiting - Clinical trials for Benzodiazepine Dependence

Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence

BABET
Start date: March 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Benzodiazepines and related molecules are among the most prescribed psychotropic treatments in France and Europe. 13.4% of the French population had at least one reimbursement of benzodiazepines in 2015, which places France second in Europe. However, the chronic use of benzodiazepines is a source of numerous complications, particularly addictive. To date, there is no authorized pharmacological treatment for benzodiazepine withdrawal. Baclofen is a gamma-aminobutyric acid (GABA)-B agonist, a pharmacological receptor that regulates GABA-A, the target of benzodiazepines. The pharmacological mechanisms of baclofen are therefore related to those of benzodiazepines. Empirical use outside of the MA has shown that baclofen can facilitate the reduction of benzodiazepines in cases of severe addiction, but this pharmaceutical interest remains to be demonstrated in a comparative study. The main objective of the project is to evaluate the efficacy of baclofen, compared to placebo, in reducing benzodiazepine doses in patients with benzodiazepine use disorder (BUD).

NCT ID: NCT05765656 Not yet recruiting - Anxiety Clinical Trials

Effectiveness of a Joint General Practitioner-Pharmacist Intervention on Benzodiazepine Deprescribing in the Elderly

BESTOPH-MG
Start date: March 15, 2023
Phase: N/A
Study type: Interventional

Benzodiazepines or related drug (BZDR) are consumed for hypnotic or anxiolytic purposes in most cases. The consequences of BZDR are multiple with an increased risk of daytime sedation, balance disorders leading to falls and fractures, cognitive disorders, road accidents and dementia. Given their comorbidities, physiological changes, and multiple medications, the elderly are more at risk of suffering from BZDR adverse events. Interprofessional collaboration has shown efficacy in improving prescribing appropriateness and may affect patients outcomes positively. Morever, motivational interviews (MI) may reduce the extent of substance abuse compared to no intervention.